F11R and neoplasm: Indeed, our results are congruent with other reports of studies in nasopharyngeal cancer, glioblastoma, non-small cell lung cancer, and breast cancer showing that elevated JAM-A expression is associated with metastasis, tumor progression, and poor prognosis [25, 26, 39–44].